Your browser doesn't support javascript.
loading
Diverse Imaging Methods May Influence Long-Term Oncologic Outcomes in Oligorecurrent Prostate Cancer Patients Treated with Metastasis-Directed Therapy (the PRECISE-MDT Study).
Bauckneht, Matteo; Lanfranchi, Francesco; Albano, Domenico; Triggiani, Luca; Linguanti, Flavia; Urso, Luca; Mazzola, Rosario; Rizzo, Alessio; D'Angelo, Elisa; Dondi, Francesco; Mataj, Eneida; Pedersoli, Gloria; Abenavoli, Elisabetta Maria; Vaggelli, Luca; Detti, Beatrice; Ortolan, Naima; Malorgio, Antonio; Guarneri, Alessia; Garrou, Federico; Fiorini, Matilde; Grimaldi, Serena; Ghedini, Pietro; Iorio, Giuseppe Carlo; Iudicello, Antonella; Rovera, Guido; Fornarini, Giuseppe; Bongiovanni, Diego; Marcenaro, Michela; Pazienza, Filippo Maria; Timon, Giorgia; Salgarello, Matteo; Racca, Manuela; Bartolomei, Mirco; Panareo, Stefano; Ricardi, Umberto; Bertagna, Francesco; Alongi, Filippo; Barra, Salvina; Morbelli, Silvia; Sambuceti, Gianmario; Belgioia, Liliana.
  • Bauckneht M; Nuclear Medicine, IRCCS Ospedale Policlinico San Martino, Genova, Italy; matteo.bauckneht@unige.it.
  • Lanfranchi F; Department of Health Sciences, University of Genova, Genova, Italy.
  • Albano D; Department of Health Sciences, University of Genova, Genova, Italy.
  • Triggiani L; Nuclear Medicine, ASST Spedali Civili di Brescia, Brescia, Italy.
  • Linguanti F; University of Brescia, Brescia, Italy.
  • Urso L; University of Brescia, Brescia, Italy.
  • Mazzola R; Radiation Oncology, ASST Spedali Civili di Brescia, Brescia, Italy.
  • Rizzo A; Nuclear Medicine, Careggi University Hospital, Florence, Italy.
  • D'Angelo E; Nuclear Medicine, Ospedale San Donato, Arezzo, Italy.
  • Dondi F; Nuclear Medicine, Oncological Medical and Specialist Department, University Hospital of Ferrara, Ferrara, Italy.
  • Mataj E; Advanced Radiation Oncology, IRCCS Sacro Cuore Don Calabria Hospital, Cancer Care Center, Negrar, Italy.
  • Pedersoli G; Nuclear Medicine, Candiolo Cancer Institute, FPO-IRCCS, Turin, Italy.
  • Abenavoli EM; Radiation Oncology, University Hospital of Modena, Modena, Italy.
  • Vaggelli L; Nuclear Medicine, ASST Spedali Civili di Brescia, Brescia, Italy.
  • Detti B; University of Brescia, Brescia, Italy.
  • Ortolan N; University of Brescia, Brescia, Italy.
  • Malorgio A; Radiation Oncology, ASST Spedali Civili di Brescia, Brescia, Italy.
  • Guarneri A; University of Brescia, Brescia, Italy.
  • Garrou F; Radiation Oncology, ASST Spedali Civili di Brescia, Brescia, Italy.
  • Fiorini M; Nuclear Medicine, Careggi University Hospital, Florence, Italy.
  • Grimaldi S; Nuclear Medicine, Careggi University Hospital, Florence, Italy.
  • Ghedini P; Radiation Oncology, Careggi University Hospital, Florence, Italy.
  • Iorio GC; Nuclear Medicine, Oncological Medical and Specialist Department, University Hospital of Ferrara, Ferrara, Italy.
  • Iudicello A; Radiotherapy, University Hospital of Ferrara, Ferrara, Italy.
  • Rovera G; Radiation Oncology, Candiolo Cancer Institute, FPO-IRCCS, Turin, Italy.
  • Fornarini G; Nuclear Medicine, AOU Città della Salute e della Scienza di Torino, University of Turin, Turin, Italy.
  • Bongiovanni D; Advanced Radiation Oncology, IRCCS Sacro Cuore Don Calabria Hospital, Cancer Care Center, Negrar, Italy.
  • Marcenaro M; Nuclear Medicine, AOU Città della Salute e della Scienza di Torino, University of Turin, Turin, Italy.
  • Pazienza FM; Nuclear Medicine, Oncology, and Haematology Department, University Hospital of Modena, Modena, Italy.
  • Timon G; Radiation Oncology, Department of Oncology, University of Turin, Turin, Italy.
  • Salgarello M; Nuclear Medicine, Oncology, and Haematology Department, University Hospital of Modena, Modena, Italy.
  • Racca M; Nuclear Medicine, AOU Città della Salute e della Scienza di Torino, University of Turin, Turin, Italy.
  • Bartolomei M; Medical Oncology 1, IRCCS Ospedale Policlinico San Martino, Genova, Italy.
  • Panareo S; Radiation Oncology, Department of Oncology, University of Turin, Turin, Italy.
  • Ricardi U; Radiotherapy, IRCCS Ospedale Policlinico San Martino, Genova, Italy; and.
  • Bertagna F; Nuclear Medicine, AOU Città della Salute e della Scienza di Torino, University of Turin, Turin, Italy.
  • Alongi F; Radiotherapy, IRCCS Ospedale Policlinico San Martino, Genova, Italy; and.
  • Barra S; Nuclear Medicine, IRCCS Ospedale Sacro Cuore Don Calabria, Negrar, Italy.
  • Morbelli S; Nuclear Medicine, Candiolo Cancer Institute, FPO-IRCCS, Turin, Italy.
  • Sambuceti G; Nuclear Medicine, Oncological Medical and Specialist Department, University Hospital of Ferrara, Ferrara, Italy.
  • Belgioia L; Nuclear Medicine, Oncology, and Haematology Department, University Hospital of Modena, Modena, Italy.
J Nucl Med ; 65(8): 1202-1209, 2024 Aug 01.
Article en En | MEDLINE | ID: mdl-38906557
ABSTRACT
Metastasis-directed therapy (MDT) has been tested in clinical trials as a treatment option for oligorecurrent prostate cancer (PCa). However, there is an ongoing debate regarding the impact of using different imaging techniques interchangeably for defining lesions and guiding MDT within clinical trials.

Methods:

We retrospectively identified oligorecurrent PCa patients who had 5 or fewer nodal, bone, or visceral metastases detected by choline or prostate-specific membrane antigen (PSMA) PET/CT and who underwent MDT stereotactic body radiotherapy with or without systemic therapy in 8 tertiary-level cancer centers. Imaging-guided MDT was assessed as progression-free survival (PFS), time to systemic treatment change due to polymetastatic conversion (PFS2), and overall survival predictor. Propensity score matching was performed to account for clinical differences between groups.

Results:

Of 402 patients, 232 (57.7%) and 170 (42.3%) underwent MDT guided by [18F]fluorocholine and PSMA PET/CT, respectively. After propensity score matching, patients treated with PSMA PET/CT-guided MDT demonstrated longer PFS (hazard ratio [HR], 0.49 [95% CI, 0.36-0.67]; P < 0.0001), PFS2 (HR, 0.42 [95% CI, 0.28-0.63]; P < 0.0001), and overall survival (HR, 0.39 [95% CI, 0.15-0.99]; P < 0.05) than those treated with choline PET/CT-guided MDT. Additionally, we matched patients who underwent [68Ga]Ga-PSMA-11 versus [18F]F-PSMA-1007 PET/CT, observing longer PFS and PFS2 in the former subgroup (PFS HR, 0.51 [95% CI, 0.26-1.00]; P < 0.05; PFS2 HR, 0.24 [95% CI, 0.09-0.60]; P < 0.05).

Conclusion:

Diverse imaging methods may influence outcomes in oligorecurrent PCa patients undergoing MDT. However, prospective, head-to-head studies, ideally incorporating a randomized design, are necessary to provide definitive evidence and facilitate the practical application of these findings.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias de la Próstata / Tomografía Computarizada por Tomografía de Emisión de Positrones / Metástasis de la Neoplasia Límite: Aged / Aged80 / Humans / Male / Middle aged Idioma: En Año: 2024 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias de la Próstata / Tomografía Computarizada por Tomografía de Emisión de Positrones / Metástasis de la Neoplasia Límite: Aged / Aged80 / Humans / Male / Middle aged Idioma: En Año: 2024 Tipo del documento: Article